ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2624

Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis

Dongze Wu1, Tingting Xu2, Isaac T. Cheng1, Steven H.M. Lam1, Jiang Yue1, Priscilla Wong1, Edmund Li1, Tena K. Li1 and Lai-Shan Tam3, 1Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, China, 2China Center for Health Development Studies, Peking University, Beijing, China; Department of Health Policy and Administration, Peking University School of Public Health, Beijing, China, Beijing, China, 3Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China, Hong Kong, Hong Kong

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologic agents, Biologics, cost containment and psoriatic arthritis, Effective

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, October 23, 2018

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be superior than switching to another anti-TNF (cycling strategy) [1,2].

The aims of the study were to evaluate the cost-effectiveness of 1) swapping strategy for established PsA and 2) immediate versus standard swapping strategy for early PsA from the Hong Kong (HK) societal perspective

Methods:

A swapping York model with life time horizon was developed for two hypothetical subpopulations:1) established PsA (age=47, HAQ=1.22, Figure A) received five swapping strategies and 2) early PsA (age=40, HAQ=0.71, Figure B) received immediate (start bDMARDs after diagnosis) or standard (initially given BSC and then start bDMARDs when HAQ increase to 1.22) use of the most cost-effective swapping strategy. Both subpopulations were further classified into mild to moderate psoriasis (MMP, PASI=0.73) and moderate to severe psoriasis (MSP, PASI=12.5). All five swapping strategies started with an anti-TNF, followed by secukinumab 300mg and then ustekinumab 45mg. The cost-effectiveness of each strategy was determined using a willingness-to-pay (WTP) threshold of £32,356/ quality-adjusted life-year (QALY) (HK Gross Domestic Product per capita).

Results:

For the base-case scenario, all five swapping strategies are cost-effective versus BSC strategy for established PsA, which are associated with greater QALY gain and lower treatment related direct costs, psoriasis cost and productivity loss. In established PsA with MMP and MSP, etanercept swapping strategy is likely to be the most cost-effective strategy with an incremental cost £9,518.93 and £9,084.58 per QALY gained over BSC strategy respectively. For early PsA with MMP and MSP, the base-case results indicated that standard etanercept swapping strategy was cost-saving (£-50,635.74 and £-67,843.32) and more effective (1.20 and 1.32 QALYs); while immediate etanercept swapping strategy was costlier (£13294.95 and £8986.16), more effective (3.82 and 3.27 QALY), and had relative low ICER (£3482.36 and £2745.35 per QALY gained) relative to BSC strategy.

Conclusion:

Swapping strategy showed favorable cost-effectiveness for established PsA as well as early PsA. The increased costs of biologic agents are offset by the gain in benefits from long-term HAQ reduction.

Reference

[1] Merola JF, et al. Semin Arthritis Rheum 2017;47:29-37

[2] Cantini F, et al. Semin Arthritis Rheum 2017;47:183-192

[3] Kane D, et al. Rheumatology (Oxford) 2003; 42:1460-8

Disclosures: This study has been partly presented at EULAR2018.

 


Disclosure: D. Wu, None; T. Xu, None; I. T. Cheng, None; S. H. M. Lam, None; J. Yue, None; P. Wong, None; E. Li, None; T. K. Li, None; L. S. Tam, None.

To cite this abstract in AMA style:

Wu D, Xu T, Cheng IT, Lam SHM, Yue J, Wong P, Li E, Li TK, Tam LS. Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/cost-effectiveness-of-swapping-strategy-for-established-psoriatic-arthritis-and-immediate-versus-standard-swapping-strategy-for-early-psoriatic-arthritis/. Accessed May 17, 2022.
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cost-effectiveness-of-swapping-strategy-for-established-psoriatic-arthritis-and-immediate-versus-standard-swapping-strategy-for-early-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.